Blueprint Medicines (BPMC) Stock Price, News & Analysis

Company Overview

Blueprint Medicines (NASDAQ:BPMC) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of targeted therapies for genomically defined cancers, rare diseases and cancer immunotherapy. Founded in 2011 and headquartered in Cambridge, Massachusetts, the company applies its proprietary kinase drug discovery platform to translate genetic insights into precision medicines. Blueprint Medicines’ approach integrates molecular profiling, predictive biomarkers and rational drug design to create therapies that address the underlying drivers of disease.

Blueprint Medicines’ commercial portfolio includes AYVAKIT (avapritinib) and GAVRETO (pralsetinib), both approved by the U.S. Food and Drug Administration for specific tumor types driven by KIT or RET alterations, respectively. In addition to its marketed products, the company maintains a robust pipeline with investigational candidates such as BLU-554 (fisogatinib) for FGFR4-driven hepatocellular carcinoma and BLU-782 for treatment of certain rare cardiovascular and pulmonary diseases. These programs leverage Blueprint Medicines’ deep expertise in kinase biology and precision oncology to advance novel therapies from discovery through clinical development.

Blueprint Medicines operates globally, with research and development facilities in Massachusetts and strategic collaborations across Europe and Asia. Through partnerships with leading biopharmaceutical companies and academic institutions, the company extends its reach to patient populations worldwide and accelerates the translation of scientific discoveries into innovative treatments. Blueprint Medicines also participates in international clinical trials to evaluate its product candidates in diverse patient cohorts and regulatory environments.

The company’s leadership team is composed of executives with decades of experience in drug discovery, clinical development and commercial operations. Chief Executive Officer Dr. Jeffrey Albers, along with a management group drawn from organizations such as Genentech, Novartis and Pfizer, guides Blueprint Medicines’ strategic direction and day-to-day operations. Supported by a board of directors and scientific advisory board, the team remains focused on delivering precision therapies that improve outcomes for patients with high-unmet-need diseases.

Key Stats

• Today's Range: $128.20 to $128.40
• 50-Day Range: $87.66 to $128.40
• 52-Week Range: $73.04 to $128.52
• Volume: 1.35 million shs
• Average Volume: 1.32 million shs
• Market Capitalization: $8.28 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $128.06
• Consensus Rating: Hold

Blueprint Medicines Stock Analysis - MarketRank™

Blueprint Medicines scored higher than 35% of companies evaluated by MarketBeat, and ranked 2194th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Blueprint Medicines has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 4 buy ratings, 17 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Blueprint Medicines has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Blueprint Medicines are expected to grow in the coming year, from ($1.28) to $0.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Blueprint Medicines is -51.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Blueprint Medicines is -51.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Blueprint Medicines has a P/B Ratio of 27.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.06% of the float of Blueprint Medicines has been sold short.

Short Interest Ratio / Days to Cover

Blueprint Medicines has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Blueprint Medicines has recently decreased by 48.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Blueprint Medicines does not currently pay a dividend.

Dividend Growth

Blueprint Medicines does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.06% of the float of Blueprint Medicines has been sold short.

Short Interest Ratio / Days to Cover

Blueprint Medicines has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Blueprint Medicines has recently decreased by 48.52%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.81

News Sentiment

Blueprint Medicines has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Blueprint Medicines this week, compared to 9 articles on an average week.

Search Interest

6 people have searched for BPMC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,249,453.00 in company stock.

Percentage Held by Insiders

Only 4.21% of the stock of Blueprint Medicines is held by insiders.

BPMC Stock Analysis - Frequently Asked Questions

How have BPMC shares performed this year?

Blueprint Medicines' stock was trading at $87.22 at the start of the year. Since then, BPMC stock has increased by 47.1% and is now trading at $128.27.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Corporation (NASDAQ:BPMC) issued its quarterly earnings results on Thursday, May, 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.32. Blueprint Medicines's revenue was up 55.5% compared to the same quarter last year.
Read the conference call transcript.

When did Blueprint Medicines IPO?

Blueprint Medicines (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BPMC
• CIK: 1597264
• Web: www.blueprintmedicines.com
• Phone: (617) 374-7580
• Fax: N/A
• Employees: 640
• Year Founded: 2011

Price Target and Rating

• Average Stock Price Target: $128.06
• High Stock Price Target: $135.00
• Low Stock Price Target: $105.00
• Potential Upside/Downside: -0.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.27
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.09 million
• Net Margins: -27.70%
• Pretax Margin: -27.38%
• Return on Equity: -64.60%
• Return on Assets: -17.22%

Debt

• Debt-to-Equity Ratio: 1.01
• Current Ratio: 2.80
• Quick Ratio: 2.75

Sales & Book Value

• Annual Sales: $508.82 million
• Price / Sales: 16.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.70 per share
• Price / Book: 27.29

Miscellaneous

• Outstanding Shares: 64,580,000
• Free Float: 61,863,000
• Market Cap: $8.28 billion
• Optionable: Optionable
• Beta: 0.89